Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer (TOPACIO)
This Phase 1/2 study will evaluate the safety and efficacy of combination treatment with niraparib and pembrolizumab (MK-3475) in patients with advanced or metastatic triple-negative breast cancer or recurrent ovarian cancer. (KEYNOTE-162)
Study Type: Interventional (Clinical Trial)
Actual Enrollment: 121 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 1/2 Clinical Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Advanced or Metastatic Triple-Negative Breast Cancer and in Patients With Recurrent Ovarian Cancer
Study Start Date: March 2016
Estimated Primary Completion Date: May 2018
Estimated Study Completion Date: February 2019
Arm:
- Experimental: niraparib plus pembrolizumab
| Category | Value |
|---|---|
| Date last updated at source | 2018-02-12 |
| Study type(s) | Interventional |
| Expected enrolment | 121 |
| Study start date | 2016-03-01 |
| Estimated primary completion date | 2018-05-01 |